Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Revisits Priorities: GMPs Awarded Same Status As R&D, Marketing

Executive Summary

Lilly is rearranging its operating priorities to put manufacturing processes on the same level as R&D and sales and marketing, CEO Sidney Taurel told investors

You may also be interested in...



FDA Drug Development Efforts Are “Revolutionary,” Lilly’s Taurel Says

FDA Commissioner McClellan's plan to accelerate drug development is "the single most encouraging story now emerging in our field," Lilly CEO Sidney Taurel declared during a Hudson Institute-sponsored luncheon in Washington, D.C. Nov. 4

FDA Drug Development Efforts Are “Revolutionary,” Lilly’s Taurel Says

FDA Commissioner McClellan's plan to accelerate drug development is "the single most encouraging story now emerging in our field," Lilly CEO Sidney Taurel declared during a Hudson Institute-sponsored luncheon in Washington, D.C. Nov. 4

Lilly GMPs Clear One Milestone; Cymbalta Launch Now Planned For Summer

Lilly plans to launch Cymbalta in summer 2004, pending a pre-approval inspection and the build-up of sufficient product inventory

Related Content

UsernamePublicRestriction

Register

PS042093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel